antibody

HER-2

MBS438341

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

monoclonal

mouse

nonconjugated

[HRB2/718]

immunocytochemistry, flow cytometry

Antibody

HER-2

[HER-2]

[p185; CD340; Verb b2 Erythroblastic Leukemia Viral Oncogene Homolog 2; Neuro/Glioblastoma Derived Oncogene Homolog]

[receptor tyrosine-protein kinase erbB-2 isoform b; Receptor tyrosine-protein kinase erbB-2; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 19 protein; neuro/glioblastoma derived oncogene homolog; tyrosine kinase-type cell surface receptor HER2; neuroblastoma/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; Metastatic lymph node gene 19 protein; MLN 19; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2; CD_antigen: CD340]

[ERBB2]

[ERBB2; ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; HER2; MLN19; NEU; NGL; MLN 19]

ERBB2_HUMAN

Monoclonal

IgG1, kappa

[HRB2/718]

Mouse

Human. Others not known

1225

Recognizes a protein of 185kDa, which is identified as c-erbB-2/HER-2/neu. Its epitope is localized in the extracellular domain. C-erbB-2/HER-2 is a member of the EGFR family. This MAb is specific and shows minimal cross-reaction with other members of the EGFR-family. Receptors of this family are located on the plasma membrane and consist of an extracellular ligand-binding domain that is connected to a large intracellular domain by a single transmembrane sequence. C-erbB-2/HER-2 protein is over-expressed in a variety of carcinomas especially those of breast and ovary.

200 ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA and 0.05% azide. Also available without BSA and azide at 1.0 mg/ml.

Store at -20 to -80 degree C. Antibody is stable for 24 months.

Flow Cytometry, Immunofluorescence

Flow Cytometry (0.5-1ug/million cells); Immunofluorescence (0.5-1ug/ml). Optimal dilution for a specific application should be determined.

Localization: Cell surface. Positive Control: SKBR-3 Cells or Breast Cancers. Human Chromosomal Location: 17q12

Immunogen: Recombinant extracellular domain of human HER-2 protein.

Utrilla JC, et al. Histopathology. 34: 60-65 (1999). 2. Wright C, et al. British Journal of Cancer. 65: 118-121 (1992). 3. Corbett IP, et al. Journal of Pathology. 161: 15-25 (1990).

54792098

NP_001005862.1

NM_001005862.2

P04626

185kDa

Adaptive Immune System Pathway (366160); Adherens Junction Pathway (83070); Adherens Junction Pathway (481); Alpha6-Beta4 Integrin Signaling Pathway (198807); Axon Guidance Pathway (105688); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); Constitutive PI3K/AKT Signaling In Cancer Pathway (685535)

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

HER2: a proto-oncogenic receptor tyrosine kinase of the EGFR family. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. Not activated by EGF, TGF- alpha and amphiregulin. Amplified in breast cancer. Overexpression induces constitutive activity, and the gene is amplified or overexpressed in up to 30% of breast cancers, correlating with poor survival. The antibody Herceptin is approved for treatment of metastatic breast cancer with HER2 amplification/overexpression. Somatic mutations seen in 4% of lung cancers and also in breast, gastric, ovarian cancer and glioblastoma. One SNP shows predisposition to breast and gastric cancer. Inhibitors: Herceptin, lapatinib, PKI-166, EKB-569, CI-1033. Protein type: EC 2.7.10.1; Oncoprotein; Membrane protein, integral; Protein kinase, TK; Kinase, protein; Protein kinase, tyrosine (receptor); TK group; EGFR family. Chromosomal Location of Human Ortholog: 17q12. Cellular Component: perinuclear region of cytoplasm; basolateral plasma membrane; cytoplasm; apical plasma membrane; integral to membrane; plasma membrane; endosome membrane; cytoplasmic vesicle; nucleus; receptor complex. Molecular Function: protein C-terminus binding; protein dimerization activity; identical protein binding; protein binding; transmembrane receptor activity; ErbB-3 class receptor binding; protein heterodimerization activity; growth factor binding; protein-tyrosine kinase activity; receptor signaling protein tyrosine kinase activity; transmembrane receptor protein tyrosine kinase activity; protein phosphatase binding; ATP binding. Biological Process: myelination; axon guidance; phosphoinositide 3-kinase cascade; positive regulation of cell adhesion; peptidyl-tyrosine phosphorylation; nerve growth factor receptor signaling pathway; wound healing; positive regulation of translation; protein amino acid autophosphorylation; heart development; motor axon guidance; signal transduction; protein amino acid phosphorylation; enzyme linked receptor protein signaling pathway; positive regulation of transcription from RNA polymerase I promoter; positive regulation of MAP kinase activity; cell surface receptor linked signal transduction; oligodendrocyte differentiation; neuromuscular junction development; epidermal growth factor receptor signaling pathway; negative regulation of immature T cell proliferation in the thymus; regulation of microtubule-based process; fibroblast growth factor receptor signaling pathway; phosphoinositide-mediated signaling; transcription, DNA-dependent; regulation of angiogenesis; positive regulation of cell growth; peripheral nervous system development; cell proliferation; positive regulation of transcription from RNA polymerase III promoter; innate immune response; positive regulation of protein amino acid phosphorylation; transmembrane receptor protein tyrosine kinase signaling pathway; positive regulation of epithelial cell proliferation. Disease: Gastric Cancer; Lung Cancer; Glioma Susceptibility 1

0.02 mg (With BSA & Azide at 0.2 mg/ml)

190 USD

0.1 mg (With BSA & Azide at 0.2mg/ml)

340

0.1 mg (Without BSA & Azide at 1mg/ml)

340